Jonathan Spicer, MD, medical director of the McGill University Health Center Thoracic Oncology Network, discusses what some of the most important findings were in regard to patient outcomes from the phase 3 trial assessing nivolumab plus platinum-doublet chemotherapy for resectable non-small cell lung cancer.
Research pharmacist Brian Wortz, PharmD, with Cancer Treatment Centers of America, said working as a pharmacist in clinical research provides interesting opportunities to be at the forefront of drug development.
Jonathan Spicer, MD, medical director of the McGill University Health Center Thoracic Oncology Network, discusses findings regarding adverse events during the phase 3 trial assessing nivolumab plus platinum-doublet chemotherapy as neoadjuvant treatment for resectable non-small cell lung cancer.
This week on Pharmacy Times, there are a number of important topics that will be covered and posted throughout the week.
Jonathan Spicer, MD, medical director of the McGill University Health Center Thoracic Oncology Network, discusses what the findings of the phase 3 CheckMate 816 trial assessing nivolumab plus platinum-doublet chemotherapy as neoadjuvant treatment for patients with resectable non-small cell lung cancer may mean for future treatment options.
Jonathan Spicer, MD, medical director of the McGill University Health Center Thoracic Oncology Network, discusses his presentation on surgical outcomes from the phase 3 CheckMate 816 trial assessing nivolumab plus platinum-doublet chemotherapy as neoadjuvant treatment for patients with resectable non-small cell lung cancer.
Guselkumab also showed promising results in the treatment of psoriatic arthritis, with improved disease activity in joints and across multiple domains through 1 year.
Cabenuva, the first long-acting injectable for the treatment of HIV, is a 2-drug copackaged product containing cabotegravir and rilpivirine.
Study highlights the importance of developing solid relationships with patients, so they are comfortable asking questions and trust pharmacists with their care.
ibrutinib (Imbruvica) plus venetoclax (Venclexta) shows complete response and complete response with incomplete bone marrow recovery rate of 56% among patients with chronic lymphocytic leukemia and small lymphocytic lymphoma.
If it were to be approved now, the drug would be used in patients with metastatic castration-resistant prostate cancer who have progressed on an androgen receptor-directed therapy and 1 to 2 taxane-based chemotherapeutics.
Jonathan Strosberg, MD, section head of the Neuroendocrine Tumor Program and vice president of Medical Oncology at the Moffitt Cancer Center, discusses the overall impact of the research assessing lutetium Lu 177 dotatate for midgut neuroendocrine tumors.
Venetoclax (Venclexta) plus fulvestrant (Faslodex) did not provide superior outcomes compared to fulvestrant monotherapy among patients with locally advanced or metastatic ER–positive, HER2-negative breast cancer.
Jonathan Strosberg, MD, section head of the Neuroendocrine Tumor Program and vice president of Medical Oncology at the Moffitt Cancer Center, discusses patients reports of their quality of life while being treated with lutetium Lu 177 dotatate for midgut neuroendocrine tumors.
Andrea Apolo, MD, a Lasker clinical research scholar and head of the Bladder Cancer Section at the National Cancer Institute, explained how results from the phase 3 trial could change the treatment opportunities for patients with aRCC, as well as the treatment landscape more broadly.
The investigative therapy targets a specific molecule that is generally only expressed on the prostate cancer cell, according to a recent interview.
Researchers estimate a 5-year overall survival rate of 42.9% for patients treated with durvalumab compared with 33.4% for those administered a placebo after chemoradiation therapy.
Jonathan Strosberg, MD, section head of the Neuroendocrine Tumor Program and vice president of Medical Oncology at the Moffitt Cancer Center, discusses some of the adverse events patients experienced during the phase 3 trial assessing lutetium Lu 177 dotatate for midgut neuroendocrine tumors.
Medical oncologist Michael Morris, MD, discussed the newest findings of the phase 3 VISION trial, which is investigating the use of 177Lu-PSMA-617 in patients with advanced prostate cancer.
Jonathan Strosberg, MD, section head of the Neuroendocrine Tumor Program and vice president of Medical Oncology at the Moffitt Cancer Center, discusses the methods used during the phase 3 trial to assess lutetium Lu 177 dotatate for midgut neuroendocrine tumors.
Andrea Apolo, MD, a Lasker clinical research scholar and head of the Bladder Cancer Section at the National Cancer Institute, explained what patients with aRCC who were given either nivolumab plus cabozantinib or sunitinib reported in regard to their quality of life during treatment.
Notably, the investigative treatment avoids many of the severe adverse effects common in traditional therapies.
Bemarituzumab is an investigational, potential first-in-class targeted antibody designed to block specific fibroblast growth factors from binding and activating FGFR2b.
Warren O, a person living with HIV for 11 years who has first-hand experience with HIV stigma, discusses his perspective on how the reduction of stigma could help to end the HIV epidemic.
Semaglutide (Wegovy) injection is indicated for use with a reduced calorie meal plan and increased physical activity to help adults with obesity or overweight, who also have weight-related medical problems, lose weight and maintain weight loss.
Research has also shown activity with sacituzumab govitecan in subsets of patients with triple-negative breast cancer, such as those with active brain metastases.
The use of 177Lu-PSMA-617 resulted in a 60% reduction in radiographic progression or death among patients with advanced prostate cancer.
Jonathan Strosberg, MD, section head of the Neuroendocrine Tumor Program and vice president of Medical Oncology at the Moffitt Cancer Center, discusses the efficacy and safety of lutetium Lu 177 dotatate for midgut neuroendocrine tumors.
In PD-L1-positive patients, tislelizumab improved median overall survival by 3.5 months with a 46% decrease in the risk of death compared with chemotherapy.
Jonathan Strosberg, MD, section head of the Neuroendocrine Tumor Program and vice president of Medical Oncology at the Moffitt Cancer Center, gives an overview of the phase 3 trial assessing lutetium Lu 177 dotatate for midgut neuroendocrine tumors.
